Corneal thickness recovers after CXL

Article

After a corneal collagen cross-linking (CXL) procedure a patient's cornea thins but then recovers towards original thickness.

After a corneal collagen cross-linking (CXL) procedure a patient's cornea thins but then recovers towards original thickness, according to a one-year follow-up study published in the Journals of Cataract and Refractive Surgery.

Dr Peter S. Hersh et al., Cornea and Laser Eye Institute, New Jersey, USA, studied 54 eyes with keratoconus and 28 eyes with ecstasia after LASIK. The outcome measures were corneal thickness at the apex, the thinnest point and the pupil centre. These were measured at baseline and 1, 3, 6 and 12 months post-CXL.

Mean preoperative thinnest pachymetry was 440.7 μm ± 52.9 SD. Apex and corneal thickness returned to baseline after 1 year. Corneal thickness recovered more rapidly in ecstasia patients than in keratoconus patients. Although the researchers found that the corneal thickness was reduced up to 3-months post-op, the baseline thickness was recovered at 3 to 6-months follow-up.

In conclusion, the baseline thickness of the cornea is recovered after CXL but the causes and possible effects of this change in thickness still need to be explained.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.